Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system.
about
Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesotheliomaPrognostic information of serial plasma osteopontin measurement in radiotherapy of non-small-cell lung cancerPrognostic impact of mRNA levels of osteopontin splice variants in soft tissue sarcoma patients.Development of fragment-specific osteopontin antibodies and ELISA for quantification in human metastatic breast cancerElevated tumor and serum levels of the hypoxia-associated protein osteopontin are associated with prognosis for soft tissue sarcoma patients.Osteopontin, asbestos exposure and pleural plaques: a cross-sectional studyElevated levels of full-length and thrombin-cleaved osteopontin during acute dengue virus infection are associated with coagulation abnormalities.Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cellsPrognostic significance of plasma osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 phase III trial.Perioperative changes in osteopontin and TGFβ1 plasma levels and their prognostic impact for radiotherapy in head and neck cancer.Update on molecular diagnostic tests in head and neck cancerProteome screening of pleural effusions identifies galectin 1 as a diagnostic biomarker and highlights several prognostic biomarkers for malignant mesotheliomaIdentification and quantification of osteopontin splice variants in the plasma of lung cancer patients using immunoaffinity capture and targeted mass spectrometry.High calcium concentration and calcium oxalate crystals cause significant inaccuracies in the measurement of urinary osteopontin by enzyme linked immunosorbent assay.
P2860
Q28535472-1630A463-103D-4025-95C3-466BAC190E29Q30316974-A790659A-9BA1-4341-96D1-7DF9D3113026Q30318127-26F8E537-9C65-4F3A-B780-212F590B836AQ33317638-0ABEDDBE-682E-4DEE-8E70-A77BE22D1848Q33551004-2934621D-EE7A-4CC3-A065-3F86A4BA2E06Q33866338-21D0142C-1517-4F26-AC09-7D1747EF24B5Q33954396-812D6806-30A6-4855-A1BA-6C1C523ED173Q34173692-613F4774-4AF1-4DD9-9470-E0C1F57169B7Q35652920-8A9275AC-D639-479B-87A6-7F44529D794BQ36238876-C29E8EC0-CB58-4490-846D-2DB7734519C5Q36798480-C9BB4535-E7F2-44D0-80D7-53AD35435288Q37623620-E87DC849-E367-4300-9C81-4506A56D3404Q39424574-977C55BA-8EF7-4E24-848C-6F9CC64C790AQ46597410-2F50D408-FB8C-4A1C-932F-F7AFCAB3BAF3
P2860
Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system.
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Plasma osteopontin levels in p ...... on the choice of ELISA system.
@ast
Plasma osteopontin levels in p ...... on the choice of ELISA system.
@en
Plasma osteopontin levels in p ...... on the choice of ELISA system.
@nl
type
label
Plasma osteopontin levels in p ...... on the choice of ELISA system.
@ast
Plasma osteopontin levels in p ...... on the choice of ELISA system.
@en
Plasma osteopontin levels in p ...... on the choice of ELISA system.
@nl
prefLabel
Plasma osteopontin levels in p ...... on the choice of ELISA system.
@ast
Plasma osteopontin levels in p ...... on the choice of ELISA system.
@en
Plasma osteopontin levels in p ...... on the choice of ELISA system.
@nl
P2093
P2860
P356
P1433
P1476
Plasma osteopontin levels in p ...... on the choice of ELISA system.
@en
P2093
Astrid Katzer
Dirk Vordermark
Gabriele Hänsgen
Harun M Said
Jürgen Dunst
Matthias Bache
Michael Flentje
Thomas Kuhnt
P2860
P2888
P356
10.1186/1471-2407-6-207
P407
P577
2006-08-15T00:00:00Z
P5875
P6179
1009260597